ロード中...
The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy
It has become apparent of late that even in tamoxifen and/or aromatase resistant breast cancers, ERα remains a bona fide therapeutic target. Not surprisingly, therefore, there has been considerable interest in developing Selective ER Degraders (SERDs), compounds that target the receptor for degradat...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2011
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3109090/ https://ncbi.nlm.nih.gov/pubmed/21501600 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcp.2011.03.031 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|